UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hierarchical propagation of probabilistic and non-probabilistic uncertainty in the parameters of a risk model

Computers & structures, 2013-09, Vol.126, p.199-213

2013

Volltextzugriff (PDF)

O‐04: INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL‐WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

HemaSphere, 2022-08, Vol.6 (Suppl), p.03-04

2022

Volltextzugriff (PDF)

S121: REDUCED RATE OF VASO‐OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL‐WORLD, MANAGED ACCESS PROGRAM (MAP)

HemaSphere, 2022-01, Vol.6 (Suppl), p.11-12

2022

Volltextzugriff (PDF)

P1491: REAL‐WORLD INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1373-1374

2022

Volltextzugriff (PDF)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Muscle & nerve, 2019-07, Vol.60 (1), p.14-24

2019

Volltextzugriff (PDF)

Empirical Comparison of Two Methods for the Bayesian Update of the Parameters of Probability Distributions in a Two-Level Hybrid Probabilistic-Possibilistic Uncertainty Framework for Risk Assessment

ASCE-ASME journal of risk and uncertainty in engineering systems. Part A, Civil Engineering, 2016-03, Vol.2 (1)

2016

Volltextzugriff (PDF)

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Neurology, 2021-01, Vol.96 (4), p.e610

2021

Volltextzugriff (PDF)

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years

Journal of neurology, 2012-05, Vol.259 (5), p.952-958

2012

Volltextzugriff (PDF)

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

Neurology, 2021-03, Vol.96 (12), p.e1595

2021

Volltextzugriff (PDF)

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Journal of neurology, 2020-07, Vol.267 (7), p.1991-2001

2020

Volltextzugriff (PDF)

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Quality of life research, 2019-08, Vol.28 (8), p.2247-2255

2019

Volltextzugriff (PDF)

Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study

Muscle & nerve, 2021-12, Vol.64 (6), p.662-669

2021

Volltextzugriff (PDF)

New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy

Muscle & nerve, 2012-06, Vol.45 (6), p.831-834

2012

Volltextzugriff (PDF)

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

Journal of the neurological sciences, 2019-12, Vol.407, p.116419-116419, Article 116419

2019

Volltextzugriff (PDF)

P27: HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW‐UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS

HemaSphere, 2022-04, Vol.6 (Suppl), p.25-26

2022

Volltextzugriff (PDF)

Estimation of a quantity of interest in uncertainty analysis: Some help from Bayesian decision theory

Reliability engineering & system safety, 2012-04, Vol.100 (93-101), p.93-101

2012

Volltextzugriff (PDF)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis

Quality of life research, 2019-08, Vol.28 (8), p.2255-2255

2019

Volltextzugriff (PDF)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Annals of clinical and translational neurology, 2020-08, Vol.7 (8), p.1327-1339

2020

Volltextzugriff (PDF)

Assessing disability in morbidly obese individuals: the Italian Society of Obesity test for obesity-related disabilities

Disability and rehabilitation, 2011-01, Vol.33 (25-26), p.2509-2518

2011

Volltextzugriff (PDF)

Sequence Analysis of the UCP1 Gene in a Severe Obese Population from Southern Italy

Journal of Obesity, 2011-01, Vol.2011 (2011), p.185-188

2011

Volltextzugriff (PDF)

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

Epidemiology and infection, 2008-11, Vol.136 (11), p.1576-1584

2008

Volltextzugriff (PDF)

Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus

Journal of clinical virology, 2010-10, Vol.49 (2), p.105-110

2010

Volltextzugriff (PDF)

Ureteroiliac Artery Fistula in a Young Woman with Short Bowel Syndrome for Radiation Enteritis

Case Reports in Medicine, 2010-01, Vol.2010 (2010), p.218-220-055

2010

Volltextzugriff (PDF)

Bayesian model of water meters degradation

Revue de statistique appliquée, 2004-03, Vol.LII (1), p.39-65

2004

Volltextzugriff (PDF)

Bayesian update of the parameters of probability distributions for risk assessment in a two-level hybrid probabilistic-possibilistic uncertainty framework

Safety, Reliability and Risk Analysis: Beyond the Horizon, 2014, p.3295-3302

1, 2014

Volltextzugriff (PDF)

1 – 25 von 848

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(749)
Mit Volltextzugriff
(714)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(501)
Life Sciences & Biomedicine
(472)
Humans
(412)
Female
(282)
Male
(246)
Middle Aged
(205)
Adult
(203)
Aged
(126)
Cardiovascular System & Cardiology
(105)
Nutrition & Dietetics
(104)
Biological And Medical Sciences
(102)
Medical Sciences
(95)
Cardiac & Cardiovascular Systems
(94)
Adolescent
(66)
Oncology
(63)
Obesity
(61)
Body Mass Index
(60)
Retrospective Studies
(59)
Risk Factors
(57)
Medicine
(56)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Hierarchical propagation of probabilistic and non-probabilistic uncertainty in the parameters of a risk model

O‐04: INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL‐WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

S121: REDUCED RATE OF VASO‐OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL‐WORLD, MANAGED ACCESS PROGRAM (MAP)

P1491: REAL‐WORLD INCIDENCE OF VASO‐OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Empirical Comparison of Two Methods for the Bayesian Update of the Parameters of Probability Distributions in a Two-Level Hybrid Probabilistic-Possibilistic Uncertainty Framework for Risk Assessment

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years

Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study

New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P27: HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW‐UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS

Estimation of a quantity of interest in uncertainty analysis: Some help from Bayesian decision theory

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Assessing disability in morbidly obese individuals: the Italian Society of Obesity test for obesity-related disabilities

Sequence Analysis of the UCP1 Gene in a Severe Obese Population from Southern Italy

Assessment of humoral and cell-mediated immunity against Bordetella pertussis in adolescent, adult, and senior subjects in Italy

Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus

Ureteroiliac Artery Fistula in a Young Woman with Short Bowel Syndrome for Radiation Enteritis

Bayesian model of water meters degradation

Bayesian update of the parameters of probability distributions for risk assessment in a two-level hybrid probabilistic-possibilistic uncertainty framework

Suchergebnisse filtern